ClinicalTrials.gg
RecruitingNCT07193420REDUCyUpdated Nov 10, 2026

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

A Phase 3 interventional study of Cyclophosphamide 35mg/kg/day and Cyclophosphamide 50mg/kg/day in GVHD - Graft-Versus-Host Disease, HSCT and Haploidentical Stem Cell Transplantation, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies testing cyclophosphamide in Graft vs Host Disease — 11 open to participants now, 22 under way, 4 of them phase 3. Cyclophosphamide · Graft vs Host Disease.

Planned enrollment
4th of 47
180 · median 35
Started
2026
with 4 others
Phase 3
4 of 48
1 open now
Primary completion
2030-09
later than 17 of 21 live
Registered
45th of 48
by date
Lead sponsor
2 of 48
Assistance Publique - Hôpitaux de Paris

Among the 48 studies testing cyclophosphamide in Graft vs Host Disease, this one is the 4th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 17 of the 21 other live ones, and was the 45th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

11 of the 48 studies testing cyclophosphamide in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing cyclophosphamide in Graft vs Host Disease, or all of them as a file.
02

Study summary

Phase III comparative, open-label, randomized (1:1) trial designed to evaluate the efficacy of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to the standard dose of 100 mg/kg, in patients undergoing haploidentical HSCT for the treatment of a hematological malignancy, two years after HSCT.

Read the detailed description

The primary endpoint is the assessment of the GREFS at 2 years after HSCT, a composite endpoint defined as the probability of survival without severe GVHD, relapse/progression of the hematological malignancy, or PTCy-associated adverse event, whichever comes first from transplantation.

03

Conditions studied

  • GVHD - Graft-Versus-Host Disease
  • HSCT
  • Haploidentical Stem Cell Transplantation

Browse trials for

Keywords

  • Cyclophosphamide toxicities
  • Cyclophosphamide dose reduction
  • Graft-Versus-Host Disease: GVHD
  • Hematopoietic stem cell transplantation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Confirmed hematological with an indication for HSCT
  • Presence of a haploidentical donor willing to donate PBSC
  • Patient planned to receive a thiotepa-based conditioning regimen
  • Provision of written Affiliation to a social security system (excluding "Aide Médicale d'État")

Exclusion criteria

Exclusion Criteria:

  • performance status \< 70%
  • \< 1 month, as determined by the attending physician
  • Acute or chronic heart failure, defined as \< 40%
  • Pulmonary dysfunction with diffusion capacity \< 50% of predicted values
  • Renal impairment with estimated (eGFR) \< 45 mL/min (calculated using the CKD-EPI formula)
  • Decompensated hemolytic anemia
  • Fanconi anemia and other DNA breakage repair disorders
  • Acute urothelial toxicity due to cytotoxic chemotherapy or radiotherapy
  • Obstruction of urinary outflow
  • Concomitant use with yellow fever vaccine and with live virus and bacterial vaccines
  • Combination with products containing Hypericum perforatum
  • Combination with medicines that are substrates for the multidrug efflux transporter P-glycoprotein (P-gp) or the organic anion transporter proteins (OATP) and for which elevated plasma concentrations are associated with serious and/or life-threatening events, e.g., bosentan, dabigatran etexilate and aliskiren
  • Active non-controlled infectious disease
  • Positive status
  • Pregnancy, breast-feeding, or refusal to use effective for the duration of the study and 6 months after the last treatment dose
  • Individuals under legal protection measures or unable to provide consent (e.g., severe neurological or psychiatric disorders, or deprivation of liberty by judicial or administrative decision)
  • to the active substance or any of the
  • Concurrent participation in another therapeutic study
  • Inability to comply with study procedures as assessed by the investigator based on objective criteria, including but not limited to:

    • Significant language barrier in the absence of adequate translation support
    • Social or geographic situation preventing follow-up and adherence to visit schedule
    • Ongoing substance abuse likely to interfere with protocol compliance
    • Documented cognitive or functional impairment not otherwise covered under legal protection
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Reduced dose

    cyclophosphamide administered at 35mg/kg/day (Adjusted body weight) on days +3 and +4

    Drug: Cyclophosphamide 35mg/kg/day

  • Active comparator
    Standard dose

    cyclophosphamide administered at 50mg/kg/day (Adjusted Body Weight) on days +3 and +4

    Drug: Cyclophosphamide 50mg/kg/day

Interventions

  • DrugCyclophosphamide 35mg/kg/day

    Drug page: CyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclophosphamide will be administered intravenously (IV) post-HSCT at the experimental dose (70 mg/kg, divided into two doses of 35 mg/kg/day (Adjusted Body Weight) on days +3 and +4).

  • DrugCyclophosphamide 50mg/kg/day

    Drug page: CyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclophosphamide will be administered intravenously (IV) post-HSCT at the standard dose (100 mg/kg, divided into two doses of 50 mg/kg/day (Adjusted Body Weight) on days +3 and +4).

06

What researchers measure

Primary outcomes

  1. GVHD-free, relapse-free, event-free survival (GREFS)

    The primary endpoint is the assessment of the GREFS at 2 years after HSCT, a composite endpoint defined as the probability of survival without severe GVHD, relapse/progression of the hematological malignancy, or PTCy-associated adverse event, whichever comes first from transplantation

    Time frame: Day 0 to first occurrence of acute grade III-IV GVHD, severe chronic GVHD, relapse, death, grade 3-4 cardiac event, or grade 3-4 BK virus-associated HC (up to 24 months post-transplant); platelet recovery (>50 × 10^9/L) assessed until Day +60

Secondary outcomes

  1. Overall survival (OS)

    Overall survival (OS) at 2 years is defined as survival irrespective of disease status

    Time frame: From transplantation until death from any cause or up to 24 months, whichever occurs first

  2. Quality of life FACT-BMT

    Quality of life compared to baseline using questionnaire: FACT-BMT (Functional Assessment of Cancer Therapy - Bone Marrow Transplant, version 4)

    Time frame: At 1, 3, 6, 12, and 24 months after HSCT

  3. Quality of life EQ-5D-5L

    Quality of life compared to baseline using questionnaire: EQ-5D-5L (EuroQol 5-Dimension, 5-Level questionnaire).

    Time frame: At 1, 3, 6, 12, and 24 months after HSCT

  4. Toxicities, infection and hematogical recovery

    Organ damage toxicities assessed by the common terminology criteria for adverse events (CTCAE) v5.0, cumulative incidences of bacterial, viral, and fungal infections, and failure to achieve neutrophil recovery (absolute neutrophil count \> 0.5 x 10\^9/L) or platelet recovery (platelet count \> 50 x 10\^9/L) after HSCT

    Time frame: From transplantation until the occurrence of the event, day +60 for hematological recovery, or up to 24 months for organ damage toxicities and infections, whichever occurs first

  5. Cumulative incidence and severity of acute and chronic GVHD assessed according to the 2014 NIH criteria

    Acute GVHD grading should be performed by the MAGIC criteria, for chronic GVHD; the time of onset of chronic GVHD will be recorded, as well as the requirement for a systemic immunosuppressive therapy and the maximum grade achieved according to the NIH Consensus Criteria

    Time frame: From transplantation until the occurrence of GVHD or death from any cause, or up to 180 days after transplantation for acute GVHD, or up to 24 months for chronic GVHD, whichever occurs first

  6. Non-relapse mortality

    Time frame: From transplantation until death without evidence of relapse or up to 24 months, whichever occurs first Description: NRM refers to death without evidence of disease relapse.

  7. Cumulative incidence of relapse

    Cumulative incidence functions (CIFs) will estimate outcomes such as relapse

    Time frame: From transplantation until the occurrence of relapse or up to 24 months, whichever occurs first

  8. Disease-free survival (DFS)

    DFS is defined as survival without relapse or progression, the endpoints will be censored at two years to address differences in follow-up between groups

    Time frame: At two years

  9. GVHD-free, relapse-free survival (GRFS)

    GRFS encompasses survival free from acute grade III-IV GVHD, chronic GVHD requiring systemic immunosuppression, or relapse

    Time frame: From transplantation until the occurrence of acute grade III-IV GVHD, severe chronic GVHD, relapse, death, or up to 24 months, whichever occurs first

  10. Cost-effectiveness

    The endpoint of the medico-economic analysis is the incremental cost-utility ratio (ICUR) at 24 months of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to the standard dose of 100 mg/kg. The incremental cost-utility ratio will be calculated in cost per QALY gained. The secondary endpoint is the incremental cost-effectiveness ratio (ICER) at 24 months. The incremental cost-effectiveness ratio will be calculated in cost per life-years gained.

    Time frame: From transplantation until 2 years

  11. Cytokine profiles

    This ancillary study will evaluate cytokine profiles in relation to PTCy doses using a multiplex test based on fluorescence-coded beads

    Time frame: Inclusion, Day 0, Day 15-35, Day 90, Day 365

  12. Gut microbiota

    This ancillary study will evaluate gut microbiota: richness based on α-diversity indexes

    Time frame: Inclusion, Day 0, Day 15-35, Day 90

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2030, 48 months after the start.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's planned 48 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Jun 2026 → Sep 2026, primary completion Jun 2030 → Sep 2030 and completion Jun 2030 → Sep 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Sep 25, 2025
StartActual
Sep 29, 2026was Jun 2026
Primary completionEst.
Sep 2030was Jun 2030
CompletionEst.
Sep 2030was Jun 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
Saint Antoine Hospital - Hematology Department is now Recruiting
Nov 10, 2026
Start date
Jun 2026→Sep 29, 2026 (actual)
Nov 10, 2026
Primary completion
Jun 2030→Sep 2030
Nov 10, 2026
Study completion
Jun 2030→Sep 2030
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    Saint Antoine Hospital - Hematology Department is now Recruiting
    Start date Jun 2026→Sep 29, 2026 (now actual)
    Primary completion Jun 2030→Sep 2030
    Study completion Jun 2030→Sep 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07193420
Responsible party
Sponsor
First posted
Sep 25, 2025
Start date
Sep 29, 2026
Primary completion
Sep 2030 (estimated)
Completion
Sep 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Mohamad MOHTY, PU-PH
Contact
mohamad.mohty@inserm.fr
00 33 1.49.28.26.20
Remy DULERY
Contact
remy.dulery@aphp.fr
Mohamad MOHTY, PU-PH
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion